ReviewPharmaceuticals (Basel, Switzerland)2020

Current Evidence on the Protective Effects of Recombinant Human Erythropoietin and Its Molecular Variants against Pathological Hallmarks of Alzheimer's Disease.

José J Jarero-Basulto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.